In a phase I trial, the co-inhibitory molecule T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), which is expressed on immune cells, is being investigated for its inhibition in relation to anti-PD1 medications for a variety of tumour types, including GB. The gene discussed is HAVCR2; the disease is neoplasm.